Document Detail


Clinical outcomes by relative docetaxel dose and dose intensity as chemotherapy for Japanese patients with castration-resistant prostate cancer: a retrospective multi-institutional collaborative study.
MedLine Citation:
PMID:  23299278     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
BACKGROUND: The aim of this study was to retrospectively investigate clinical outcomes by relative dose and dose intensity of docetaxel (DOC) as chemotherapy for Japanese patients with castration-resistant prostate cancer (CRPC). METHODS: A total of 145 CRPC patients who received more than 4 courses of DOC chemotherapy at 14 hospitals between 2005 and 2011 were enrolled. Patients were divided into two groups-those receiving a higher or lower dose (mg/m(2)) or dose intensity (mg/m(2)/week). Differences between the groups regarding treatment outcomes and adverse events (AEs) were determined. Additionally, prognostic factors predictive of cancer-specific survival (CSS) in these patients were identified by both univariate and multivariate analysis. RESULTS: The total patient group underwent a mean of 11.2 ± 7.4 DOC cycles, and the mean CSS after therapy was 15.6 ± 10.1 months. The higher-dose group had a better prostate-specific antigen (PSA) response than the lower-dose group. However, there was no significant difference between the groups in prognosis after DOC chemotherapy. Leukopenia and neutropenia were observed more frequently in the higher-dose group. Serum biomarkers (including PSA, lactate dehydrogenase and alkaline phosphatase), hemoglobin levels and presence of pain at initiation of chemotherapy, as well as the PSA nadir level on first-line hormone therapy, all were significant predictors of CSS. CONCLUSIONS: In the Japanese population, relatively low-dose DOC chemotherapy had no deleterious effect on the CSS of CRPC patients, and a lower incidence of AEs occurred, in spite of a diminished PSA response compared with those receiving a higher dose.
Authors:
Naoto Kamiya; Hiroyoshi Suzuki; Takeshi Ueda; Naohide Sato; Hiroomi Nakatsu; Kazuo Mikami; Nobuo Sato; Kazushi Nomura; Koichiro Akakura; Tatsuya Okano; Takemasa Ooki; Yukio Naya; Sho Ota; Motoyuki Masai; Tomohiko Ichikawa
Related Documents :
10773408 - Inhibition by methionine of pancreatic carcinogenesis in hamsters after initiation with...
18723908 - Efficacy of two dose regimes of intravenous immunoglobulin in rh hemolytic disease of n...
11992708 - Vaccination of donkeys against babesia equi using killed merozoite immunogen.
17943548 - The effect of resveratrol on prevention of the development of postoperative adhesions i...
22520338 - Efficacy of slow-release collar formulations of imidacloprid/flumethrin and deltamethri...
3965628 - A controlled trial of the effect of 4-hydroxypyrazolopyrimidine (allopurinol) on the to...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-9
Journal Detail:
Title:  International journal of clinical oncology     Volume:  -     ISSN:  1437-7772     ISO Abbreviation:  Int. J. Clin. Oncol.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-9     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9616295     Medline TA:  Int J Clin Oncol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Department of Urology, Toho University Sakura Medical Center, 564-1 Shimoshizu, Sakura, Chiba, 285-8741, Japan, naoto.kamiya@med.toho-u.ac.jp.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Degraded DNA may induce discordance of KRAS status between primary colorectal cancer and correspondi...
Next Document:  Clinical variables for predicting metastatic renal cell carcinoma patients who might not benefit fro...